new_adrs_0322_1328|THRX|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_adrs_0322_1328|THRX|Long Name|1|1|Theseus Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Theseus Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Theseus Pharmaceuticals Inc Inventories (Quarterly) (USD)|Theseus Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Theseus Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Theseus Pharmaceuticals Inc Book Value (Quarterly) (USD)|Theseus Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Theseus Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Theseus Pharmaceuticals Inc EV to Revenues|Theseus Pharmaceuticals Inc EV to Earnings|Theseus Pharmaceuticals Inc EV to Free Cash Flow|Theseus Pharmaceuticals Inc EV to Assets (Quarterly)|Theseus Pharmaceuticals Inc PS Ratio|Theseus Pharmaceuticals Inc PE Ratio|Theseus Pharmaceuticals Inc Price to Book Value|Theseus Pharmaceuticals Inc PEG Ratio|Theseus Pharmaceuticals Inc Debt to Equity Ratio|Theseus Pharmaceuticals Inc Dividend Yield|Theseus Pharmaceuticals Inc Shareholder Yield (TTM)|Theseus Pharmaceuticals Inc Percent of Shares Outstanding Short|Theseus Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Theseus Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Theseus Pharmaceuticals Inc Return on Invested Capital|Theseus Pharmaceuticals Inc Quality Ratio Score|Theseus Pharmaceuticals Inc Momentum Score|Theseus Pharmaceuticals Inc Beta (1Y)|Theseus Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Theseus Pharmaceuticals Inc Institutional Investor Ownership Percentage|Theseus Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Theseus Pharmaceuticals Inc Total Employees (Annual)|Theseus Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Theseus Pharmaceuticals Inc Shares Outstanding|Theseus Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Theseus Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Theseus Pharmaceuticals Inc Payout Ratio|Theseus Pharmaceuticals Inc Quick Ratio (Quarterly)|Theseus Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Theseus Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Theseus Pharmaceuticals Inc Effective Tax Rate (TTM)|Theseus Pharmaceuticals Inc Return on Equity|Theseus Pharmaceuticals Inc Net Income (TTM) (USD)|Theseus Pharmaceuticals Inc Revenue (TTM) (USD)|Theseus Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Theseus Pharmaceuticals Inc Revenue (Quarterly) (USD)|Theseus Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Theseus Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Theseus Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Theseus Pharmaceuticals Inc Net Income (Quarterly) (USD)|Theseus Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Theseus Pharmaceuticals Inc Price (USD)|Theseus Pharmaceuticals Inc Total Return Price (USD)|Theseus Pharmaceuticals Inc Enterprise Value (USD)|Theseus Pharmaceuticals Inc 30-Day Average Daily Volume|Theseus Pharmaceuticals Inc 1 Year Price Returns (Daily)
new_adrs_0322_1328|THRX|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_adrs_0322_1328|THRX||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly
new_adrs_0322_1328|THRX||5|5|121.666666667|121.666666667|0|121.666666667|0|121.666666667|121.666666667|121.666666667|0|121.666666667|121.666666667|0|0|0|0|0|0|0|1.45283018868|0|0|1.44642857143|0|15.1111111111|0|121.666666667|121.666666667|0|0|0|0|0|30|152.333333333|53.5|152.333333333|25.3333333333|0|121.666666667|0|0|152.333333333|0|0|0|0|0|0|0|0|152.333333333|152.333333333|152.333333333|0|1.44642857143|1.44642857143|1.44642857143|1.4578313253|0
new_adrs_0322_1328|THRX||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|0|0|0|0|53|0|0|112|0|9|0|3|3|0|0|0|0|0|1|3|2|3|6|0|3|0|0|3|0|0|0|0|0|0|0|0|3|3|3|0|112|112|112|83|0
new_adrs_0322_1328|THRX||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_adrs_0322_1328|THRX|202009|202009|202009||||||||||||||||||||||||||||||||||25.3675||-0.0563||||||-0.0563|||||||||0.154|-1.429|-1.429||||||
new_adrs_0322_1328|THRX|202012|202012|202012|8.57|8.457||0.001||42.884|1.595|41.289||-34.27|-34.27|||||||||||||||1.132|0|||||||25.3675||-0.1139|||35.864|||-0.1139|||||||||0.4|-2.89|-2.89||||||
new_adrs_0322_1328|THRX|202106|202106|202106|99.325|97.586||0||146.136|3.966|142.17||-44.066|-45.55|||||||||||||||1.766|0||||||||||||35.864||||||||||||||||||||
new_adrs_0322_1328|THRX|202109|202109|202109|91.486|90.404||0||147.764|5.68|142.084||-50.145|-52.922|||||||||||||||2.392|0|||||||35.864|16|-0.2056|35.864||35.864|||-0.2056|||||||||2.378|-7.372|-7.372||||||
new_adrs_0322_1328|THRX|202110|202109|202109||||||||||||||||||||||0||1.0871|||||||||21.1789||||38.7027||||||||||||||||||17.12|17.12|572.1862||
new_adrs_0322_1328|THRX|202111|202109|202109||||||||||||||||||||||0||2.9802|||||||||25.0075||||38.7027||||||||||||||||||14.31|14.31|463.4316|190435.5667|
new_adrs_0322_1328|THRX|202112|202112|202112|247.971|244.662||0.011||4.495|3.68|0.815||246.434|-61.578||||||||1.9914|||0||2.9374||1.002|0.004|||||||38.7026|26|-0.24|38.7027||38.7026|||-0.24||||-20.347|||||3.637|-8.656|-8.656||12.68|12.68|246.0882|301796.3|
new_adrs_0322_1328|THRX|202201|202112|202112|||||||||||||||||||1.4496|||0||3.0309|||||||||||||||||||||||||||||||9.23|9.23|112.5639|236925.3|
new_adrs_0322_1328|THRX|202202|202112|202112|||||||||||||||||||1.5862|||0||3.058|||||||||||||||||||||||||||||||10.1|10.1|146.2353|91377.8|
new_adrs_0322_1328|THRX|202203|202203|202203|||||||||||||||||||2.2788|||0|||||||||||||||38.7027||||||||||||||||||14.51|14.51|316.9142|45358.4|